Virtual Library
Start Your Search
Y. Eralp
Author of
-
+
P3.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC (ID 208)
- Event: WCLC 2015
- Type: Poster
- Track: Treatment of Advanced Diseases - NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P3.01-049 - Concomitant Chemoradiotherapy with Etoposide & Cisplatin versus Docetaxel & Cisplatin in Locally Advanced Non-Small Cell Lung Cancer (ID 1453)
09:30 - 09:30 | Author(s): Y. Eralp
- Abstract
Background:
There is currently no consensus regarding which chemotherapy regimen is best to administer with radiotherapy in patients with locally advanced non–small-cell lung cancer. Here, our aim was to compare the outcome of patients treated with either etoposide-cisplatin (EP) or docetaxel-cisplatin (DP) in this curative setting.
Methods:
The patients treated with concurrent radiotherapy with either EP or DP with from 2004 to 2012 were identified. Patients whose medical records and follow up information obtained in details were included to this retrospective study. Survival rates were compared using Cox proportional hazards regression models with adjustments for confounding provided by propensity score methods.
Results:
A total of 105 patients were treated with concurrent chemoradiotherapy for locally advanced (IIB-IIIA-IIIB) non-small cell lung cancer in Istanbul University, Institute of Oncology between 2004 and 2012. Totally 50 patients (median age 54 yr; 32-70 yr) given concurrent EP and 55 patients (median age 55 yr; 37-73) given concurrent DP were enrolled to analyses. There was no statistically significant difference in baseline clinicopathological features including age, gender, performance status, and weight loss, histological subtype, primary lung side, clinical T, N and TNM stages between 2 groups. In univariate analysis, median overall survival of patients treated with EP was found to be higher than that of patients treated with DP (41 months versus 20 months, p= 0.003). Multivariate analysis further revealed survival advantage with EP as compared to DP (hazard ratio [HR], 0.46; 95% CI, 0.25 to 0.83) (p=0.009). Toxicity profile of 2 treatment groups were found to be similar except that pulmonary toxicity was higher in DP group compared to EP (grade 3-4: 0 versus 6%, p= 0.024).
Conclusion:
Concurrent chemoradiotherapy with EP may provide more favorable outcome than that of DP with acceptable safety profile.
-
+
P3.04 - Poster Session/ Biology, Pathology, and Molecular Testing (ID 235)
- Event: WCLC 2015
- Type: Poster
- Track: Biology, Pathology, and Molecular Testing
- Presentations: 1
- Moderators:
- Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P3.04-013 - Clinicopathological Data's of Advanced NSCLC Patients with ROS1 Gene Rearrangement and of Clinical Responses to Crizotinib in TURKEY (ID 1214)
09:30 - 09:30 | Author(s): Y. Eralp
- Abstract
Background:
The ROS1 oncogene encodes an orphan receptor tyrosine kinase related to anaplastic lymphoma kinase (ALK), leukocyte receptor tyrosine kinase, and members of the insulin receptor family. Chromosomal rearrangement of ROS1 occurs in a variety of human cancers, including non-small cell lung cancer (NSCLC). Crizotinib (XALKORI®) is , first-in-class, small molecule tyrosine kinase inhibitor of ALK, ROS1, and c-MET. It has been approved in several countries for the treatment of advanced ALK-positive NSCLC. A global phase I study of crizotinib includes expansion cohorts for patients with molecularly defined tumors, including a cohort of patients with advanced NSCLC harboring ROS1 fusions.
Methods:
Between January 2014 and January 2015, a total of 542 patients with advanced NSCLC was enrolled. They were all negative for EGFR mutation and also ALK rearrangement. All of the cases of ROS1 rearrangement were identified through a break-apart ROS1 fluorescence in-situ hybridization (FISH) assay together with immunohistocemical ROS1 (D4D6 clone) positivity. Treatment All patients received at least one prior line of standard therapy for advanced NSCLC. After that Crizotinib was administered orally at the standard dose of 250 mg twice daily in continuous 28-day cycles.
Results:
ROS1 rearrangements were found in 5 cases of 542 lung cancer samples, the total incidence was 0,9%. All the tumors of the positive cases were adenocarcinoma. The ROS-1 rearrangements were more frequent in female patients (80%) than male ones. They were all young patients median age 39 years old. The majority of patients had never smoked (60%) and the others were light-smoker. The first patient has been receiving Crizotinib therapy for thirteen months and all patients are still alive. Two patients (40%) achieved a complete response, 2 patients (40%) achieved a partial response. Last patient was started Crizotinib therapy in the March of 2015.
Conclusion:
Patients with ROS1-positive NSCLC have similar demographic characteristics to those with ALK-positive NSCLC. ROS1 rearrangement test is recommended for all patients whose tumors were negative EGFR and ALK. ROS1 rearrangement defines a second molecular subset of NSCLC for which crizotinib is a highly active treatment. This is the first report presenting clinico-pathological data of the patients harboring ROS1 rearrangement in TURKEY.
